4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
MediPal Holdings Corporation (7459) operates in the Medical Distribution industry and is headquartered in Tokyo, Japan with about 13,024 employees. Its market capitalization is roughly JPY 572 billion. In the fiscal year ended 2026-03-31, 7459 reported JPY 3.82T in revenue and JPY 42.5B in net income.
Medipal Holdings Corporation engages in the prescription pharmaceutical wholesale business in Japan.
Interactive charts & full statements →
| Income statement | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 |
|---|---|---|---|---|
| Total Revenue | JPY 3.82T | JPY 3.67T | JPY 3.56T | JPY 3.36T |
| Gross Profit | JPY 261.0B | JPY 255.8B | JPY 246.7B | JPY 224.3B |
| Operating Income (EBIT) | JPY 53.2B | JPY 55.6B | JPY 47.3B | JPY 49.0B |
| Net Income | JPY 42.5B | JPY 40.3B | JPY 41.5B | JPY 38.8B |
JPY; JPYM / JPYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Cash flow | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|---|
| Dividends Paid | (JPY 13.2B) | (JPY 12.5B) | (JPY 11.2B) | (JPY 9.7B) | — |
JPY; JPYM / JPYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|---|
| Total Assets | JPY 1.92T | JPY 1.82T | JPY 1.80T | JPY 1.71T | — |
| Total Liabilities | JPY 1.13T | JPY 1.07T | JPY 1.06T | JPY 1.02T | — |
JPY; JPYM / JPYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive 7459 viewer.
This page in other languages: עברית · Русский · Español · Português · 中文 · العربية · Français · Italiano · 日本語 · Deutsch · فارسی · हिन्दी
About TickerBase · Data methodology & sources · Privacy · Terms